Evaluation of sweet taste sensitivity in type-II Diabetes Mellitus patients

Background: The objective is to evaluate the sweet taste sensitivity among type-II diabetes mellitus patients. Methods: This is a cross sectional study consisted of 227 subjects (127 type-II Diabetic patients & 100 non diabetic individuals) of both the genders and age matched. Sweet taste sensitivity tests were done using different concentrations of glucose solution and compared among the diabetic patients with FBS more than 180mg/dl and diabetic patients with FBS less than 180mg/dl and also compared among the diabetic patients and non diabetic individuals. The final concentration at which patient was able to perceive the taste was recorded. statistical analysis was done using Student’s unpaired T test. Pvalues of < 0.05 were considered to be statistically significant. Results: The mean of sweet taste sensitivity among diabetic patients with FBS >180 mg/dl was 6245 mg/l and the mean of sweet taste sensitivity in the diabetic patients with FBS <180 mg/dl was 2249mg/l with P<0.001 which is significant. The mean of sweet taste sensitivity among diabetic patients with FBS >180 mg/dl was 6245mg/l and the mean of sweet taste sensitivity in the non diabetic individuals was 1979mg/l with P<0.01 which is significant. the mean of sweet taste sensitivity among diabetic patients with FBS <180 mg/dl was 2249 mg/l and the mean of sweet taste sensitivity in the non diabetic individuals was 1979mg/l with P>0.05 which is not significant. Conclusion: In our study it was concluded that type-II Diabetes Mellitus patients have lesser sensitivity for the sweet taste. Loss of sensitivity leads to the increase in sugar consumption being the risk factor for worsening the disease.

Download Full-text

Associations of Demographic, Clinical and Laboratory Profiles of Patients with type II Diabetes Mellitus with its Microvascular Complications in Bangladesh

10.21203/rs.3.rs-24860/v1 ◽

2020 ◽

Author(s):

Mamunur Rashid ◽

Abdul Mukit ◽

Khawza Iftekhar Uddin Ahmed ◽

Raqibul Mostafa ◽

Sharmin Parveen ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type Ii Diabetes ◽

Microvascular Complications ◽

Significant Risk ◽

Type Ii Diabetes Mellitus ◽

Cross Sectional Study ◽

Cardiac Autonomic Neuropathy ◽

Diabetic Patients ◽

Type Ii ◽

Cross Sectional

Abstract Objective: The aim of this study was to investigate the associations of makers from demographic, clinical, and laboratory profiles with microvascular complications in a cohort of type II diabetic population in Bangladesh. Methods: In this cross-sectional study 103 participants [47 Men and 56 Women; Age 40~70 years] having type II diabetes for more than 10 years were randomly recruited during their routine visits to a major Diabetic Hospital in Dhaka, Bangladesh. The associations of prevalence of microvascular complications [Cardiac Autonomic Neuropathy(CAN), Diabetic Peripheral Neuropathy(DPN), Diabetic Nephropathy(Nep), Diabetic Retinopathy(Ret)] with demographic, clinical, and laboratory profiles were assessed by multivariate logistic regression (p<0.05 and Odds ratio (OR)> 1.0). Results: The prevalence rates of CAN, DPN, Ret and Nep were 68%, 43.69%, 6.8%, and 4.8% respectively. The overall prevalence of diabetic-associated microvascular complication is 94.36% in this cohort of diabetic patients. BMI (p=0.0330, OR=1.90) and HbA1c (p=0.0535, OR=3.08) were found to be the most significant risk factors in the development of all microvascular complications. However, HbA1c for CAN; HbA1c, Microalbuminuria and Urinary creatinine for DPN; years of Diabetes, Systolic blood pressure and albumin creatinine ratio for Nep, HbA1c and Microalbuminuria for Ret were found to be most significantly associated in this Diabetes patients’ cohort. Conclusion: The proportion of microvascular complications was found to be significantly high among patients with Type II diabetes mellitus in this cohort. Controlling HbA1c could help reduce all four types of complications. However, controlling microalbuminuria could prevent DPN and Ret. This emphasizes the need for screening and prevention program toward early, symptomless identification of type II diabetes microvascular complications.

Download Full-text